TY  - JOUR
TI  - Differences between Hyperprogressive Disease and
Progressive Disease in Patients Receiving Immunotherapy
AB  - Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not
respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall
survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate
HPD and PD.
Methods: Ninety-five patients treated with ICIs with progression according to response evaluation criteria ın solid
tumors criteria in the first control imaging were included. HPD was defined according to Russo's work. The PILE scoring
system, which includes pan-immune-inflammation value, lactate dehydrogenase, and Eastern Cooperative Oncology
Group PS, was followed. The relationship between PILE score and HPD was analyzed.
Results: The median OS of all cohorts was 11.18 months. The patients in the HPD group had decreased OS (4.77 vs.
13.94 months, p<0.001) and progression-free survival (PFS) (1.89 vs. 3.16 months, p<0.001) compared with those in the
PD group. The risk of HPD was higher than the risk of PD in patients with a high PILE score (p=0.001).
Conclusion: In this study, we showed that patients treated with ICI with a higher PILE score are at greater risk for
HPD. The PILE score may be a biomarker to differentiate HPD from PD.
AU  - YILMAZ, Feride
AU  - Yildirim, Hasan cagri
AU  - yalcin, suayib
AU  - erman, mustafa
AU  - Guner, Gurkan
AU  - Yaşar, Serkan
AU  - Aktaş, Burak Yasin
AU  - Aktepe, Oktay Halit
AU  - TABAN, HAKAN
AU  - Dizdar, Omer
AU  - GÜVEN, Deniz Can
AU  - AKSOY, SERCAN
AU  - Kılıçkap, Saadettin
DO  - 10.14744/ejmo.2022.78280
PY  - 2022
JO  - Eurasian Journal of Medicine and Oncology
VL  - 6
IS  - 1
SN  - 2587-2400
SP  - 59
EP  - 63
DB  - TRDizin
UR  - http://search/yayin/detay/521045
ER  -